Infectious complications of chronic lymphocytic leukaemia: Pathogenesis, spectrum of infection, preventive approaches

Keyphrases

• Chronic Lymphocytic Leukemia 100%
• Infectious Complications 100%
• Preventive Approach 100%
• Immunosuppression 25%
• Candida 25%
• Mycobacterium 25%
• Rituximab 25%
• Monoclonal Antibody 25%
• Vaccination Strategy 25%
• Alemtuzumab 25%
• Infection Risk 25%
• Listeria 25%
• Fludarabine 25%
• Herpesvirus 25%
• Immune Suppression 25%
• Immune Therapy 25%
• Cellular Immune Response 25%
• Pneumocystis 25%
• Aspergillus 25%
• Therapy-related 25%
• Pathogenesis of Infection 25%
• Immune Defect 25%
• Antimicrobial Prophylaxis 25%
• Hypogammaglobulinemia 25%
• Purine Analogues 25%
• Immunoglobulin Prophylaxis 25%
• Predisposing Factors 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Infection 100%
• Chronic Lymphatic Leukemia 100%
• Infectious Complication 100%
• Infectious Agent 20%
• Candida 20%
• Pneumocystis 20%
• Antiinfective Agent 20%
• Immunoglobulin 20%
• Immune Deficiency 20%
• Rituximab 20%
• Aspergillus 20%
• Disease Predisposition 20%
• Herpesviridae 20%
• Purine Derivative 20%
• Immunoglobulin Deficiency 20%
• Listeria 20%
• Monoclonal Antibody 20%
• Immunotherapy 20%
• Purine 20%
• Fludarabine 20%
• Mycobacteria 20%
• Alemtuzumab 20%

Medicine and Dentistry

• Infection 100%
• B-Cell Chronic Lymphocytic Leukemia 100%
• Infectious Complication 100%
• Immunosuppressive Treatment 40%
• Pathogen 20%
• Immunoglobulin 20%
• Antiinfective Agent 20%
• Fludarabine 20%
• Rituximab 20%
• Herpesviridae 20%
• Disease Predisposition 20%
• Immune Deficiency 20%
• Purine 20%
• Hypogammaglobulinemia 20%
• Aspergillus 20%
• Listeria 20%
• Monoclonal Antibody 20%
• Immunotherapy 20%
• Mycobacteria 20%
• Alemtuzumab 20%